# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $130 price target.
JMP Securities analyst Reni Benjamin reiterates Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and maintains $12...
Stephens & Co. analyst Sudan Loganathan initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Overweight rating...
Leerink Partners analyst Andrew Berens upgrades Blueprint Medicines (NASDAQ:BPMC) from Underperform to Market Perform and ra...
Goldman Sachs analyst Terence Flynn maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from ...